Cargando…

P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATE

Detalles Bibliográficos
Autores principales:	Belada, D., Leppä, S., Wahlin, B. E., Nijland, M., Christensen, J. H., de Vos, S., Holte, H., Linton, K. M., Abbas, A., Wang, L., Dinh, M., Elliott, B., Falchi, L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430698/ http://dx.doi.org/10.1097/01.HS9.0000847408.61609.bd

Ejemplares similares

S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS
por: Sureda, Anna, et al.
Publicado: (2023)

P1214: SUBCUTANEOUS EPCORITAMAB + R-CHOP FOR FIRST-LINE TREATMENT OF PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA: PHASE 1/2 UPDATE
por: Clausen, M. R., et al.
Publicado: (2022)

P1215: PRELIMINARY PHASE 1/2 RESULTS OF SUBCUTANEOUS EPCORITAMAB + R-DHAX/C IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
por: Cordoba, R., et al.
Publicado: (2022)

P1116: HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R-CHOP IN PREVIOUSLY UNTREATED (1L) PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA, INCLUDING DOUBLE/TRIPLE-HIT: EPCORE NHL-2 UPDATE
por: Roost Clausen, Michael, et al.
Publicado: (2023)

P1213: SUBCUTANEOUS EPCORITAMAB WITH GEMOX INDUCED HIGH RESPONSE RATES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
por: Wahlin, B. E., et al.
Publicado: (2022)

PB2133: ASSESSING SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS EPCORITAMAB IN NOVEL COMBINATIONS WITH ANTI-NEOPLASTIC AGENTS IN PATIENTS WITH NON-HODGKIN LYMPHOMA IN A PHASE 1B/2, OPEN-LABEL STUDY
por: Sehn, L. H., et al.
Publicado: (2022)

Entourage: the immune microenvironment following follicular lymphoma
por: Wahlin, B E, et al.
Publicado: (2012)

1135. The PEST Approach to Choosing Antimicrobial Therapy
por: Davar, Kusha, et al.
Publicado: (2020)

P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)
por: Sehn, L. H., et al.
Publicado: (2022)

1135. Strongyloides Stercolaris Serology in Transplant Patients: To Test or Not?
por: Rivera, Karla Rivera, et al.
Publicado: (2018)

P1154: EFFICACY OF SUBCUTANEOUS EPCORITAMAB VS AXI-CEL IN R/R DLBCL CAR T-NAIVE AND CAR T-ELIGIBLE PATIENTS: AN INDIRECT COMPARISON
por: Thieblemont, Catherine, et al.
Publicado: (2023)

Selection On synonymous Mutations Revealed by 1135 Genomes of Arabidopsis thaliana
por: Wei, Lai
Publicado: (2020)

Observations concerning the beam loss during run 1135 - A possible explanation for beam loss during vertical steering
por: Vos, L
Publicado: (1980)

1,135 Genomes Reveal the Global Pattern of Polymorphism in Arabidopsis thaliana
Publicado: (2016)

Analysis of 1135 gut metagenomes identifies sex-specific resistome profiles
por: Sinha, Trishla, et al.
Publicado: (2018)

P1118: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
por: Jurczak, Wojciech, et al.
Publicado: (2023)

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
por: Mhibik, Maissa, et al.
Publicado: (2023)

Epcoritamab-bysp (Epkinly) – A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma
por: Riaz, Rumaisa, et al.
Publicado: (2023)

Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas
por: Li, Tommy, et al.
Publicado: (2022)

Expression, purification and structural analysis of the Pyrococcus abyssi RNA binding protein PAB1135
por: Luz, Juliana S, et al.
Publicado: (2010)

Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin's Lymphomas
por: Gunnellini, Marco, et al.
Publicado: (2012)

P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
por: Nastoupil, L., et al.
Publicado: (2022)

Context-dependent and -independent selection on synonymous mutations revealed by 1,135 genomes of Arabidopsis thaliana
por: Chu, Duan, et al.
Publicado: (2021)

Outcome in a series of 1135 twin pregnancies: does the type of conception play a role?
por: Prats, Pilar, et al.
Publicado: (2022)

An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date
por: Yilmaz, Umut, et al.
Publicado: (2021)

Relieving Emergency Department Burden During COVID-19: Section 1135 Waivers for Dental Case Diversion
por: Patel, Nisarg A., et al.
Publicado: (2020)

The Al(61.49)Mn(11.35)Ni(4) phase in the Al–Mn–Ni system
por: Hu, Qifa, et al.
Publicado: (2022)

LASSBio-1135: A Dual TRPV1 Antagonist and Anti-TNF-Alpha Compound Orally Effective in Models of Inflammatory and Neuropathic Pain
por: Lima, Cleverton K. F., et al.
Publicado: (2014)

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial
por: Thieblemont, Catherine, et al.
Publicado: (2023)

The frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populations
por: Rudkin, Teresa M, et al.
Publicado: (2006)

Hepatitis B virus‐associated follicular lymphoma presents T‐cell inflamed phenotype and response to lenalidomide
por: Wang, Nan, et al.
Publicado: (2021)

P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS
por: Rosenthal, Allison, et al.
Publicado: (2023)

PB2266: TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5)
por: Vitolo, Umberto, et al.
Publicado: (2023)

1135. The 2018 Global Point Prevalence Survey of Antimicrobial Consumption and Resistance: Pediatric Results from 26 Canadian Hospitals
por: Lefebvre, Marie-Astrid, et al.
Publicado: (2019)

HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma
por: Stevens, Wendy B.C., et al.
Publicado: (2020)

Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal
por: Geyer, Mark B., et al.
Publicado: (2023)

P1169: COMPARISON OF REAL-WORLD CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA TREATED WITH EPCORITAMAB VS CHEMOIMMUNOTHERAPY
por: Ip, Andrew, et al.
Publicado: (2023)

Lenalidomide-Associated ITP
por: Herold, Christina I., et al.
Publicado: (2011)

Corrections: “Synthesis of Sulfonamides and Evaluation of Their Histone Deacetylase (HDAC) Activity” by Jung et al., Molecules 2007, 12, 1125-1135
por: McPhee, Derek J.
Publicado: (2009)

A Case of Cardiogenic Stroke With a Novel LMNA Variant (c. 1135C>A; p.Leu379Ile)
por: Tokuda, Naoki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2rmfs8f7lfjvekft71o6c1f3g4